Moderna says norovirus vaccine trial on FDA clinical hold
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Moderna Stock Rebounds Despite Vaccine Maker's Wider-Than-Expected Loss
Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, or $2 ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
Moderna price target lowered to $25 from $35 at Wolfe Research
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Investor's Business Daily on MSN19h
Moderna Stock Reverses As CEO Stephane Bancel Deflects Concerns Over RFK Jr.
Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.